文献速递儿科影像骨肌PETCTMR

18F-FDG PET对儿童软组织肉瘤初始分期与治疗计划的影响

The impact of 18F-FDG PET on initial staging and therapy planning of pediatric soft-tissue sarcoma patients.
PubMed 文献 · Pediatr Radiol · 2019-10-18

回顾性分析2007年3月至2017年10月26例初诊儿童软组织肉瘤患者,比较18F-FDG PET与CT/MRI的病灶检出。26个原发灶各法检出相同;84个转移灶中PET与CT/MRI共同检出16个、仅PET检出12个(主要为淋巴结)、仅CT/MRI检出56个(主要为肺转移);PET使26例中5例(19%)治疗计划改变。作者认为PET对初始分期有价值,尤其淋巴结转移,但需进一步研究明确其作用。

要点

  • 儿童软组织肉瘤初始分期中PET与CT/MRI对原发灶检出相同(26/26)。
  • PET额外检出12个转移灶(主要为淋巴结),但漏诊56个(主要为肺转移)。
  • PET使5/26例(19%)治疗计划改变。

核心结论

  • 18F-FDG PET对儿童软组织肉瘤初始精准分期有价值,尤其检出淋巴结转移,可纳入初始检查流程。
  • 鉴于该组肿瘤相对罕见且异质,需进一步研究以明确18F-FDG PET在小儿软组织肉瘤初始分期和治疗计划中的作用。

研究设计与样本

  • 回顾性研究,自医院信息系统数据库获取2007年3月至2017年10月因软组织肉瘤行18F-FDG PET/CT的病例。
  • 纳入26例初诊时接受18F-FDG PET及MRI和/或CT的患者,年龄1.3–17.9岁(中位6岁),女性15例。
  • 全部26例有诊断性CT可比,18例有MRI可比;横断面影像与PET平均间隔5.9天(范围0–30天)。
  • 由PET与同期诊断性CT、MRI独立阅片,记录各方法检出的原发灶和转移灶数目,并复习病历获取最终诊断、分期和治疗计划。

关键影像表现/征象

  • 26个原发灶由18F-FDG PET检出者与CT、MRI相同(26/26)。
  • 84个转移灶中,PET与CT、MRI共同检出16个,仅PET检出12个(主要为淋巴结转移),仅CT和MRI检出56个(主要为肺转移)。

临床应用与阅片要点

  • 作者认为18F-FDG PET对儿童软组织肉瘤初始精准分期有价值,尤其用于检出淋巴结转移。
  • 作者提出18F-FDG PET可纳入该类患者的初始检查流程。
  • 阅片时需注意PET对肺转移的检出不及CT和MRI(本组56个转移灶仅CT/MRI检出)。
  • 作者指出需进一步研究以明确18F-FDG PET在小儿软组织肉瘤初始分期和治疗计划中的作用。

局限性

  • 作者指出该组肿瘤相对罕见且异质,需进一步研究以明确18F-FDG PET在小儿软组织肉瘤初始分期和治疗计划中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Soft-tissue sarcomas in children are a histologically heterogenous group of malignant tumors accounting for approximately 7% of childhood cancers. There is a paucity of data on the value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) for initial staging and whether PET influenced management of these patients.

OBJECTIVE: The aim of this analysis is to assess the use of 18F-FDG PET exclusively, and as a supplement to cross-sectional imaging in comparison to typical imaging protocols (CT and magnetic resonance imaging [MRI]) for initial staging as well as therapy planning in pediatric soft-tissue sarcoma patients.

MATERIALS AND METHODS: The list of 18F-FDG PET/CT performed for soft-tissue sarcoma between March 2007 and October 2017 was obtained from the Hospital Information System database. Twenty-six patients who had received 18F-FDG PET, MRI and/or CT at initial diagnosis were included in the study. 18F-FDG PET and concurrent diagnostic CT and MRI at initial staging were independently reviewed to note the number of primary and metastatic lesions detected by each modality. A chart review was conducted to collect information on final diagnosis, staging and treatment plan.

RESULTS: During the study period, 26 patients (15 females) ages 1.3-17.9 years (median age: 6 years) had received 18F-FDG PET/CT at initial diagnosis of soft-tissue sarcoma. Diagnostic CT was available for comparison in all 26 patients and MRI was available in 18 patients. The mean interval between cross-sectional imaging and 18F-FDG PET was 5.9 days (range: 0-30 days). All 26 primary lesions were equally detected by 18F-FDG PET compared to CT and MRI. From 84 metastatic lesions, 16 were detected by PET as well as CT and MRI, 12 by 18F-FDG PET only (included mainly lymph node metastases) and 56 by CT and MRI only (included mainly lung metastases). 18F-FDG PET changed therapy planning in 5 patients out of 26 (19%) by showing additional lesions not detected by CT and MRI.

CONCLUSION: 18F-FDG PET proved to be a valuable tool for precise initial staging of pediatric soft-tissue sarcoma patients, especially in detecting lymph node metastasis, and could be included in their initial work-up. Given the relative rarity and heterogeneity of this group of tumors, additional investigations are required to definitely establish a role for 18F-FDG PET in the initial staging and therapy planning of soft-tissue sarcoma in the pediatric population.

来源:Pediatr Radiol,查看原文。版权归原作者所有。

引用

  1. Elmanzalawy A, Vali R, Chavhan GB, et al. The impact of 18F-FDG PET on initial staging and therapy planning of pediatric soft-tissue sarcoma patients. Pediatr Radiol. 2019. PMID: 31628508. doi:10.1007/s00247-019-04530-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。